Will ETA-antibody arouse new interest in cancer therapeutics?

摘要

Although endothelin receptor type A (ETA) is emerging as a novel anticancer target, previously only small molecule drugs have been available as ETA antagonists. Ju and colleagues have successfully developed a functional anti-ETA antibody for colorectal cancer.